# To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

> **NCT00706719** · PHASE2 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 17 (actual)

## Conditions studied

- Secondary Hypogonadism

## Interventions

- **DRUG:** 25 mg Androxal
- **DRUG:** Testim 1%

## Key facts

- **NCT ID:** NCT00706719
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706719, "To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00706719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*